Clinical trial
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
NCT00262483 · Vertex Pharmaceuticals Incorporated, Industry · Completed
Key facts
| NCT number | NCT00262483 |
|---|---|
| Title | Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C |
| Official title | A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C |
| Lead sponsor | Vertex Pharmaceuticals Incorporated, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | VX-950, ribavirin, peginterferon alfa-2a |
| Enrollment | 12 |
| Start date | Dec 1, 2005 |
| Completion | Apr 1, 2006 |
| First posted | Dec 6, 2005 |
| Last update posted | Dec 21, 2007 |
| Countries | Puerto Rico, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: